Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

Impact · against what's priced in

The news is largely neutral for Incyte as the mentioned JAK2 difficulties do not outweigh the dominant Jakafi revenue drivers. For Prelude and Pfizer, the developments represent new pipeline milestones and competitive positioning that are not yet reflected in established price assumptions.

INCY−0.10: Doesn't touch the price's assumptions
The price assumes: The existing, smaller royalty and milestone streams (Olumiant, Iclusig, Pemazyre, Tabrecta) at their present run-rates.

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

What matters in this story

Medpace: 3 Key Takeaways for Long-Term Investors

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

What matters in this story

Medpace: 3 Key Takeaways for Long-Term Investors

How each ticker is affected

Connected tickers

Track these names every morning.

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path

Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings

Great News for AbbVie Stock Investors

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

What matters in this story

Next reads from the same story arc

Medpace: 3 Key Takeaways for Long-Term Investors

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

What matters in this story

Next reads from the same story arc

Medpace: 3 Key Takeaways for Long-Term Investors

How each ticker is affected

Connected tickers

Track these names every morning.

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path

Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings

Great News for AbbVie Stock Investors

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports